Rethinking the appraisal and approval of drugs for type 2 diabetes
- Naci, Huseyin
- Lehman, Richard
- Wouters, Olivier J.
- Goldacre, Ben
- Yudkin, John S
Publication date
January 2015
DOI Publisher
BMJ ISSN
1756-1833 Citation count (estimate)
8Abstract
The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of the regulatory standards for licensing, reimbursing, and adopting new drugs. Regulatory reform is needed to improve the real-world therapeutic value of anti-diabetic drugs
Add to ORKG